Osteogenic differentiation of human umbilical cordderived mesenchymal stem cells promoted byoverexpression of osterix

被引:1
作者
Huang, Shengyun [1 ]
Jia, Shanshan [2 ]
Liu, Guijun [1 ]
Fang, Dong [3 ]
Zhang, Dongsheng [1 ]
机构
[1] Shandong Univ, Prov Hosp, Dept Oral & Maxillofacial Surg, Jinan 250021, Shandong, Peoples R China
[2] Shandong Univ, Prov Hosp, Dept Orthodont, Jinan 250021, Shandong, Peoples R China
[3] Shandong Univ, Prov Hosp, Dept Oral Radiol, Jinan 250021, Shandong, Peoples R China
关键词
Osteogenic differentiation; osterix; umbilical cord-derived mesenchymal stem cells; TRANSCRIPTION FACTOR OSTERIX; HUMAN BONE-MARROW; OSTEOBLAST DIFFERENTIATION; IN-VITRO; PROLIFERATION; OSTEOPONTIN; CORD; MINERALIZATION; EXPRESSION; SURVIVAL;
D O I
10.5372/1905-7415.0706.236
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Background: Umbilical cord-derived mesenchymal stem cells (UC-MSCs) are considered to be multipotent mesenchymal stem cells that are easily induced to differentiate into functional osteoblasts both in vitro and in vivo. Osterix (Osx), a novel zinc-finger-containing transcription factor of the Sp family, is required for osteoblast differentiation and bone formation. Objective: We investigated the effect of Osx on the proliferation and osteogenic differentiation of the UC-MSCs. Method: The primary UC-MSCs were isolated and cultured. An Osx-expressing plasmid (pEGFP-Osx) was constructed and transfected into UC-MSCs. Then expression of bone morphogenesis-related genes, proliferation rate, alkaline phosphatase activity, and mineralization were examined to evaluate the osteogenic potential of the Osx gene-modified UC-MSCs. Result: UC-MSCs transfected with pEGFP-Osx exhibited apparent osteogenic differentiation as determined by increased activity of alkaline phosphatase, the formation of mineralized nodules and the expression of related osteoblastic genes. Conclusion: These results confirmed the ability of Osx to enhance osteoblast differentiation of UC-MSCs in vitro, and the Osx gene-modified UC-MSCs are potential as novel cell resources of bone tissue engineering.
引用
收藏
页码:743 / 752
页数:10
相关论文
共 41 条
[1]   Differentiation potential of a mouse bone marrow stromal cell line [J].
Allan, EH ;
Ho, PWM ;
Umezawa, A ;
Hata, J ;
Makishima, F ;
Gillespie, MT ;
Martin, TJ .
JOURNAL OF CELLULAR BIOCHEMISTRY, 2003, 90 (01) :158-169
[2]   Biological basis of bone formation, remodeling, and repair - Part II: Extracellular matrix [J].
Allori, Alexander C. ;
Sailon, Alexander M. ;
Warren, Stephen M. .
TISSUE ENGINEERING PART B-REVIEWS, 2008, 14 (03) :275-283
[3]   Advances in the osteoblast lineage [J].
Aubin, JE .
BIOCHEMISTRY AND CELL BIOLOGY, 1998, 76 (06) :899-910
[4]   Comparison of proliferative and multilineage differentiation potential of human mesenchymal stem cells derived from umbilical cord and bone marrow [J].
Baksh, Dolores ;
Yao, Raphael ;
Tuan, Rocky S. .
STEM CELLS, 2007, 25 (06) :1384-1392
[5]  
Beck GR, 1998, J CELL BIOCHEM, V68, P269, DOI 10.1002/(SICI)1097-4644(19980201)68:2<269::AID-JCB13>3.0.CO
[6]  
2-A
[7]   Bone tissue engineering and repair by gene therapy [J].
Betz, Volker M. ;
Betz, Oliver B. ;
Harris, Mitchel B. ;
Vrahas, Mark S. ;
Evans, Christopher H. .
FRONTIERS IN BIOSCIENCE-LANDMARK, 2008, 13 :833-841
[8]   Cell-type-dependent up-regulation of in vitro mineralization after overexpression of the osteoblast-specific transcription factor Runx2/Cbfa1 [J].
Byers, BA ;
Pavlath, GK ;
Murphy, TJ ;
Karsenty, G ;
García, AJ .
JOURNAL OF BONE AND MINERAL RESEARCH, 2002, 17 (11) :1931-1944
[9]   Osterix, a transcription factor for osteoblast differentiation, mediates antitumor activity in murine osteosarcoma [J].
Cao, Y ;
Zhou, ZC ;
de Crombrugghe, B ;
Nakashima, K ;
Guan, H ;
Duan, XP ;
Jia, SF ;
Kleinerman, ES .
CANCER RESEARCH, 2005, 65 (04) :1124-1128
[10]   Disparate mesenchyme-lineage tendencies in mesenchymal stem cells from human bone marrow and umbilical cord blood [J].
Chang, Yu-Jen ;
Shih, Daniel Tzu-Bi ;
Tseng, Ching-Ping ;
Hsieh, Tzu-Bou ;
Lee, Don-Ching ;
Hwang, Shiaw-Min .
STEM CELLS, 2006, 24 (03) :679-685